Persistence of antibodies at 5–6 years of age for children who had received a primary series vaccination with a pentavalent whole-cell pertussis vaccine and a first booster with a pentavalent acellular pertussis vaccine: immunogenicity and tolerance of second booster with a tetravalent acellular vaccine at 5

Persistence of antibodies at 5–6 years of age for children who had received a primary series vaccination with a pentavalent whole-cell pertussis vaccine and a first booster with a pentavalent acellular pertussis vaccine: immunogenicity and tolerance of second booster with a tetravalent acellular vaccine at 5–6 years of age

Published:2004-03 Issue:11-12 Volume:22 Page:1406-1414
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Langue Jacques,Matisse Noëlle,Pacoret Patrick,Undreiner François,Boisnard Florence,Soubeyrand Benoı̂t

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference31 articles.

1. Epidemiological estimate of anti-pertussis vaccination efficacy during epidemics in community [Estimation épidémiologique de l’efficacité de la vaccination anticoquelucheuse au cours d’épidémies en collectivité];Baron;Arch. Pédiatr.,1997

2. Avis du conseil supérieur d’hygiène publique de France du 13 mars 1998. Calendrier vaccinal 1998. Bulletin Epidémiologique Hebdomadaire 1998; No. 15.

3. La Vaccination contre la Coqueluche des nourrissons. Avis du Conseil Supérieur d’Hygiène Publique de France. Bulletin Epidémiologique Hebdomadaire 2001; No. 19.

4. Langue J, David T, Roussel F, Pines E, Hoffenbach A. Safety and immunogenicity of DTaP-IPV and Act-Hib(tm) vaccines administered either combined or separately to infants at 2, 3 and 4 months of age. In: 15th Annual Meeting of European Society for Paediatric Infectious Diseases in Paris; 1997 [Abstract].

5. Mallet E, Hoffenbach A, Pines E, Salomon H. Immunogenicity of the fourth dose of a combined DTaP-IPV/Act-Hib(tm) vaccine administered at 15 months of age to children primed either at 2, 3, and 4 or at 2, 4, and 6 months of age. In: 15th Annual Meeting of European Society for Paediatric Infectious Diseases in Paris; 1997 [Abstract].

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immuno-persistence after the 4th and 5th dose of inactivated polio vaccines in school-aged children;2024-01-30

2. Immuno-persistence of the different primary polio vaccine schedules and immunogenicity of the booster dose by sabin inactivated or bivalent oral poliovirus vaccine in children aged 4 years: an open-label, randomised, controlled phase 4 trial in China;The Lancet Regional Health - Western Pacific;2023-05

3. Immunogenicity and immune persistence in 4-year-old children completing four doses of Sabin strain or wild strain inactivated poliovirus vaccine: A phase IV, open-labeled, parallel-controlled observational study;Vaccine;2023-05

4. Poliovirus Vaccine—Inactivated;Plotkin's Vaccines;2023

5. Review of scientific evidence to support recommendations of the full-dose DTaP-IPV vaccination in pre-school age children in Italy;Expert Review of Vaccines;2022-11-27